Literature DB >> 12222653

The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-beta for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study.

M Kainuma1, N Ogata, T Kogure, K Kohta, N Hattori, T Mitsuma, K Terasawa.   

Abstract

Patients with chronic hepatitis C, with a high serum viral load (> or = 1 Meq/ml) and genotype 1b seem to be resistant to interferon (IFN) therapy. To evaluate the efficacy of a herbal medicine (Mao-to) in combination with natural IFN-beta for the treatment of these patients, eighteen Japanese patients were enrolled in this study. Every patient received 6 million units (MU) of IFN-beta intravenously daily for 8 weeks. Mao-to was given orally 3-4 times a day during the IFN-beta administration, Sixteen of the 18 patients (89%) became negative for serum HCV RNA at the end of treatment, but only 2 of them (11%) remained negative for the virus RNA at 6 months of follow-up. Serum ALT levels normalized in 17 patients (94%) at 2 weeks of follow-up after the cessation of therapy, and 11 patients (61%) retained normal ALT levels for more than 6 months of follow-up. This rate of biochemical response was high as compared with that of therapy with IFN-beta alone (19%) in the largest IFN-beta trial in Japan. Serum hyaluronic acid levels were decreased significantly from 147.0 +/- 110.5 ng/ml to 77.4 +/- 67.4 ng/ml in the sustained biochemical response group (P = 0.003). None of the patients needed to interrupt therapy because of side effects of IFN-beta. Thus, Mao-to administration together with IFN-beta treatment could increase the sustained biochemical response rate, and reduce liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12222653     DOI: 10.1078/09447110260571571

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  3 in total

Review 1.  Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.

Authors:  Reina Sasaki; Tatsuo Kanda; Shingo Nakamoto; Yuki Haga; Masato Nakamura; Shin Yasui; Xia Jiang; Shuang Wu; Makoto Arai; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-05-18

Review 2.  Is interferon-beta an alternative treatment for chronic hepatitis C?

Authors:  Ricardo Moreno-Otero; María Trapero-Marugán; Elena Gómez-Domínguez; Luisa García-Buey; José A Moreno-Monteagudo
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

3.  Mao-to Prolongs the Survival of and Reduces TNF-alpha Expression in Mice with Viral Myocarditis.

Authors:  Zhu Shijie; Junji Moriya; Jun'ichi Yamakawa; Rui Chen; Takashi Takahashi; Hiroyuki Sumino; Takeshi Nakahashi; Kunimitsu Iwai; Shigeto Morimoto; Nobuo Yamaguchi; Tsugiyasu Kanda
Journal:  Evid Based Complement Alternat Med       Date:  2008-02-24       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.